Japanese pharmaceutical giant Eisai Co. Ltd. and Nihon Medi-Physics Co. Ltd. have entered into a collaboration agreement...
Singapore: French biopharmaceutical company, Poxel, an innovative drug developer for type 2 diabetes, has succesfully co...
Japan's leading pharmaceutical company Eisai Co. Ltd. has launched its in-house developed novel anticancer agent Lenvima...
Singapore: Isis Pharmaceuticals and AstraZeneca have made a strategic collaboration to discover and develop antisense th...
Singapore: Researchers have begun enrolling participants in to a multicenter international clinical trial to test whethe...
Singapore: US-based Biogen, a leading developer of therapies for neurodegenerative diseases has inked a pact with Japan'...
Singapore: Janssen-Cilag International NV (Janssen) submitted a marketing authorization application to the European Medi...
Singapore: Thailand's former science and technology (S&T) minister, Professor Yongyuth Yuthavong, and his team have ...
Johnson & Johnson (J&J) has announced the start of a safety and immunogenicity clinical trial in Sierra Leone of...
Singapore: Singapore's ASLAN pharmaceuticals recently announced that the Food and Drug Administration (FDA) has granted ...
Singapore: Taiwan's TaiGen Biotechnology has initiated first burixafor trial for relapsed or refractory acute myeloid le...
Singapore: Bayer's anticoagulant drug, Xarelto (rivaroxaban), has been approved by the China Food and Drug Administratio...
Singapore: Taiwanese company ScinoPharm and US-based Foresee Pharmaceuticals have signed an investment agreement to form...
Singapore: Australian biotechnology company, Novogen's lead candidate product, TRXE-009, has shown a positive result in ...
Singapore: Australian drug delivery technology company, Phosphagenics has achieved succes in its multi-dose oxymorphone ...
Singapore: Australia based Viralytics has initiated a clinical trial to assess its oncolytic virus, Cavatak, in combinat...
Singappore: US Food and Drug Administration (FDA) has granted orphan drug designation to chemotherapy drug candidate Can...
Tokyo: Japan's pharma giant Eisai Co Ltd announced that its European regional headquarters Eisai Europe Ltd has submitte...
